Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Oncimmune Holdings Plc LSE:ONC London Ordinary Share GB00BYQ94H38 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.75 -1.66% 44.55 44.10 45.00 46.00 44.50 46.00 14,223 16:35:17
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.5 -9.8 -13.4 - 31

Oncimmune Holdings PLC PDMR Dealing

21/09/2022 2:16pm

UK Regulatory (RNS & others)


Oncimmune (LSE:ONC)
Historical Stock Chart


From Sep 2022 to Dec 2022

Click Here for more Oncimmune Charts.

TIDMONC

RNS Number : 1888A

Oncimmune Holdings PLC

21 September 2022

Oncimmune Holdings plc

("Oncimmune" or the "Company")

PDMR Dealing

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, has been notified that Dr Adam Mark Hill, PDMR and Chief Executive Officer, today purchased 8,005 ordinary shares of GBP0.01 each in the Company ("Ordinary Shares") for GBP0.624599 per share.

Following this transaction, Dr Hill has a total interest in the Company of 73,872 Ordinary Shares, representing approximately 0.11 per cent of the Company's issued share capital of 69,475,480.

In addition, Dr Hill holds options over a total of 3,490,862 Ordinary Shares, representing approximately 5.02 per cent of the Company's issued share capital.

This announcement, including the notification below, is made in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.

Notification and public disclosure of transactions by person discharging managerial responsibilities and persons closely associated with them:

 
       Details of the person discharging managerial responsibilities 
  1     / person closely associated 
 a)    Name                                   Dr Adam Mark Hill 
      -------------------------------------  -------------------------------------- 
       Reason for the notification 
  2 
      ----------------------------------------------------------------------------- 
 a)    Position/status                        Chief Executive Officer 
      -------------------------------------  -------------------------------------- 
 b)    Initial notification                   Initial Notification 
        /Amendment 
      -------------------------------------  -------------------------------------- 
       Details of the issuer, emission allowance market participant, 
  3     auction platform, auctioneer or auction monitor 
      ----------------------------------------------------------------------------- 
 a)    Name                                   Oncimmune Holdings plc 
      -------------------------------------  -------------------------------------- 
 b)    LEI                                    213800HCYIWT6YPI1I02 
      -------------------------------------  -------------------------------------- 
       Details of the transaction(s): section to be repeated 
  4     for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      ----------------------------------------------------------------------------- 
 a)    Description of the                     Ordinary Shares of GBP0.01 each 
        financial instrument, 
        type of instrument 
 
       Identification code                    ISIN: GB00BYQ94H38 
 
 b)    Nature of the transaction              Purchase of Ordinary Shares 
      -------------------------------------  -------------------------------------- 
 c)    Price(s) and volume(s) 
                                              -------------------  -------------- 
                                               Price(s)             Volume(s) 
                                              -------------------  -------------- 
    GBP0.624599                                                     8,005 
   --------------------------------------------------------------  -------------- 
 
 d)    Aggregated information                 N/A - single transaction 
 
  - Aggregated volume 
 
  - Price 
 
 e)    Date of the transaction                21 September 2022 
      -------------------------------------  -------------------------------------- 
 f)    Place of the transaction               London Stock Exchange, AIMX 
      -------------------------------------  -------------------------------------- 
 

For further information:

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

contact@oncimmune.co.uk

Singer Capital Markets (Nominated Adviser and Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

+44 (0)20 7496 3000

WG Partners (Joint Broker)

David Wilson, Nigel Barnes, Erland Sternby

+44 (0)20 3705 9321

Investor Relations:

John Goold

IR@oncimmune.com

About Oncimmune

ImmunoINSIGHTS Service Business

Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. The ImmunoINSIGHTS service business leverages Oncimmune's technology platform and methodologies across multiple diseases, to offer life-science organizations actionable insights for therapies across the development and product lifecycle. Our core immune-profiling technology is underpinned by our library of over eight thousand immunogenic proteins, one of the largest of its kind. This helps identify trial participants and patients into clinically relevant subgroups, enabling development of targeted and more effective treatments.

Oncimmune's ImmunoINSIGHTS service business is based at the Company's discovery research centre in Dortmund, Germany. The business platform enables life science organizations to optimize drug development and delivery, leading to more effectively targeted and safer treatments for patients.

The ImmunoINSIGHTS development team is based in the US and Europe and Oncimmune is seeking to replicate the Dortmund facility in the US in the medium term.

EarlyCDT Product Business

Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market estimated to grow to GBP3.8bn by 2024. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programs, globally.

Oncimmune's diagnostic products business is located at its laboratory facility in Nottingham, UK.

For more information, visit www.oncimmune.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHUAAORUSUKUAR

(END) Dow Jones Newswires

September 21, 2022 09:16 ET (13:16 GMT)

1 Year Oncimmune Chart

1 Year Oncimmune Chart

1 Month Oncimmune Chart

1 Month Oncimmune Chart
Your Recent History
LSE
ONC
Oncimmune
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20221203 22:13:50